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ABSTRACT
Objective To analyse the role of the PTPN22 and CSK
genes, previously associated with autoimmunity, in the
predisposition and clinical phenotypes of giant cell
arteritis (GCA).
Methods Our study population was composed of 911
patients diagnosed with biopsy-proven GCA and 8136
unaffected controls from a Spanish discovery cohort and
three additional independent replication cohorts from
Germany, Norway and the UK. Two functional PTPN22
polymorphisms (rs2476601/R620W and rs33996649/
R263Q) and two variants of the CSK gene (rs1378942
and rs34933034) were genotyped using predesigned
TaqMan assays.
Results The analysis of the discovery cohort provided
evidence of association of PTPN22 rs2476601/R620W
with GCA (PFDR=1.06E-04, OR=1.62, CI 95% 1.29 to
2.04). The association did not appear to follow a
speciﬁc GCA subphenotype. No statistically signiﬁcant
differences between allele frequencies for the other
PTPN22 and CSK genetic variants were evident either in
the case/control or in stratiﬁed case analysis. To conﬁrm
the detected PTPN22 association, three replication
cohorts were genotyped, and a consistent association
between the PTPN22 rs2476601/R620W variant and
GCA was evident in the overall meta-analysis
(PMH=2.00E-06, OR=1.51, CI 95% 1.28 to 1.79).
Conclusions Our results suggest that the PTPN22
polymorphism rs2476601/R620W plays an important
role in the genetic risk to GCA.
INTRODUCTION
Giant cell arteritis (GCA) is a chronic vasculitis that
shows a complex aetiology derived from the inter-
action between both genetic and environmental
factors.1 Similar to most immune-related disorders,
the highest susceptibility signals belong to the
human leukocyte antigen region. However, differ-
ent studies have highlighted that genes involved in
inﬂammation pathways may also be implicated in
GCA susceptibility.2 In spite of these ﬁndings, the
genetic background of this condition is still poorly
understood.
Although the aetiology of GCA remains unclear,
it is well known that innate and adaptive immune
responses are involved in its pathogenesis. Several
lines of evidence indicate that this vasculitis is a
T cell-mediated disease with both Th17 and Th1
cells contributing to inﬂammation. While Th1
response is associated with chronically persistent
vascular lesions, Th17 immunity appears to be
more important for acute manifestations, both sys-
temically and in the blood vessels.3 4
The PTPN22/CSK pathway is a master regulator
of autoimmunity, with a key role in the negative
control of the signalling mediated by the T cell
receptor (TCR).5 Interestingly, several single-
nucleotide polymorphisms (SNPs) located within
these two genes have been associated with auto-
immunity,6–11 suggesting that this is one of the
molecular pathways shared by different auto-
immune disorders.
Regarding PTPN22, it has been reported that
two autoimmune disease-associated variants,
rs2476601 (R620W) and rs33996649 (R263Q)
inﬂuence the function of the protein.12 13 On the
other hand, two CSK polymorphisms, rs34933034
and rs1378942, were recently identiﬁed as suscepti-
bility factors for systemic sclerosis 11 and systemic
lupus erythematosus (SLE),10 respectively. A func-
tional role for the CSK genetic variant
rs34933034*A in SLE patients has been proposed
in a recent study.10
Based on this, we decided to assess the role of
the disease-associated PTPN22 and CSK poly-
morphisms in both predisposition to and the clin-
ical phenotypes of GCA.
METHODS
Study population
A total of 911 GCA patients and 8136 unrelated
healthy controls were included in this study. First,
we analysed a discovery cohort of 623 GCA
patients and 1729 healthy controls of Spanish
Caucasian ancestry. Subsequently, three independ-
ent replication cohorts were analysed (72 GCA and
937 controls from Germany; 60 GCA and 271
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controls from Norway; 156 GCA and 5199 controls from the
UK). Case and control sets were matched by geographical origin
and ethnicity, but not by age, which may represent a limitation
of the study. PTPN22 rs2476601 genotype data from the
control population of Germany were obtained from Hüffmeier
et al,14 since this set matched geographically and ethnically our
German GCA cohort. More detailed information about the UK
controls can be obtained from Morgan et al.15 Informed
written consent from all participants and approval from the
local ethical committees were obtained in accordance with the
tenets of the Declaration of Helsinki. All patients had a positive
temporal artery biopsy (disruption of the internal elastic
laminae with inﬁltration of mononuclear cells into the arterial
wall with or without multinucleated giant cells) and fulﬁlled the
1990 American College of Rheumatology classiﬁcation criteria
for GCA.16 In the subphenotype analysis, the patients
were stratiﬁed according to manifestations of polymyalgia
rheumatica (PMR) and the presence or absence of visual ischae-
mic manifestations (VIM; if they experienced transient
visual loss including amaurosis fugax, permanent visual loss or
diplopia) and irreversible occlusive disease (IOD; if they had
at least one of the following features: permanent visual loss,
stroke or occlusive disease in the upper extremities or lower
extremities).
Genotyping methods
Genomic DNA was extracted from peripheral white blood cells
using standard procedures. Two SNPs located within PTPN22,
rs2476601/R620W and rs33996649/R263Q, and two SNPs
located within CSK, rs1378942 and rs34933034, were geno-
typed using the TaqMan allelic discrimination assay technology
on a 7900HT Fast Real-Time PCR System, both from Applied
Biosystems (Foster City, California, USA). For the UK samples,
rs2476601/R620W was genotyped by direct sequencing.
Statistical analysis
The overall statistical power of the analysis, according to Power
Calculator for Genetic Studies 2006 software (http://www.sph.
umich.edu/csg/abecasis/CaTS/), is shown in online supplementary
table S1. Plink (v1.07) (http://pngu.mgh.harvard.edu/purcell/plink/)
and StatsDirect V.2.6.6 (StatsDirect Ltd, Cheshire, UK) were used
to perform 2×2 contingency tables and χ2 test and/or Fisher’s
exact test. ORs and 95% CIs were obtained according to Woolf ’s
method. The Benjamini and Hochberg (1995) step-up false discov-
ery rate (FDR) control correction for multiple testing17 was
applied to the p values of the discovery cohort. After correction,
p values lower than 0.05 were considered statistically signiﬁcant.
The allelic combinations were tested using Plink and Haploview
(V.4.2). The analysis of the combined data from all populations
was performed using Plink and StatsDirect. Breslow–Day (BD) test
method was used to estimate the homogeneity among populations.
Pooled analyses were performed by Mantel–Haenszel test under
ﬁxed effects.
RESULTS
After genotyping, no divergence from Hardy–Weinberg
equilibrium was observed either in controls or cases (p>0.01),
and control allelic frequencies were similar to those previously
reported in equivalent European Caucasian populations.8 10 11
First, we conducted an association study in a case–control set
of Spanish Caucasian origin. As shown in table 1, when allelic
frequencies were compared between cases and controls, a clear
Table 1 Genotype and allele distribution of PTPN22 rs2476601, rs33996649 and CSK rs1378942, rs34933034 in Spanish biopsy-proven GCA
patients and healthy controls
SNP Locus 1/2 Subgroup (N)
Genotype, N (%)
MAF (%)
Allele test
1/1 1/2 2/2 p Value* PFDR† OR (CI 95%)‡
rs2476601 PTPN22 A/G Controls (n=1729) 13 (0.75) 200 (11.57) 1516 (87.68) 6.54
GCA (n=623) 4 (0.64) 119 (19.10) 500 (80.26) 10.19 2.66E-05 1.06E-04 1.62 (1.29 to 2.04)
PMR+ (n=259) 2 (0.77) 53 (20.46) 204 (78.76) 11.00 2.26E-04 9.02E-04 1.77 (1.30 to 2.40)
VIM+ (n=168) 1 (0.60) 36 (21.43) 131 (77.98) 11.31 1.03E-03 4.10E-03 1.82 (1.27 to 2.62)
IOD+ (n=96) 2 (2.08) 21 (21.88) 73 (76.04) 13.02 5.47E-04 2.19E-03 2.14 (1.38 to 3.33)
rs33996649 PTPN22 T/C Controls (n=1729) 4 (0.23) 110 (6.36) 1615 (93.41) 3.41
GCA (n=623) 1 (0.16) 39 (6.26) 583 (93.58) 3.29 0.838 0.919 0.96 (0.67 to 1.38)
PMR+ (n=259) 0 (0.00) 12 (4.63) 247 (95.37) 2.32 0.191 0.382 0.67 (0.37 to 1.23)
VIM+ (n=168) 0 (0.00) 12 (7.14) 156 (92.86) 3.57 0.878 0.878 1.05 (0.57 to 1.92)
IOD+ (n=96) 0 (0.00) 6 (6.25) 90 (93.75) 3.13 0.831 0.831 0.91 (0.40 to 2.10)
rs1378942 CSK C/A Controls (n=1729) 281 (16.25) 798 (46.15) 650 (37.59) 39.33
GCA (n=623) 129 (20.71) 230 (36.92) 264 (42.38) 39.17 0.919 0.919 0.99 (0.87 to 1.13)
PMR+ (n=259) 55 (21.24) 99 (38.22) 105 (40.54) 40.35 0.658 0.756 1.04 (0.86 to 1.26)
VIM+ (n=168) 34 (20.24) 69 (41.07) 65 (38.69) 40.77 0.605 0.807 1.06 (0.85 to 1.33)
IOD+ (n=96) 20 (20.83) 39 (40.63) 37 (38.54) 41.15 0.616 0.822 1.08 (0.80 to 1.45)
rs34933034 CSK A/G Controls (n=1729) 72 (4.16) 537 (31.06) 1120 (64.78) 19.69
GCA (n=623) 21 (3.37) 176 (28.25) 426 (68.38) 17.50 0.091 0.182 0.86 (0.73 to 1.02)
PMR+ (n=259) 10 (3.86) 79 (30.50) 170 (65.64) 19.11 0.756 0.756 0.96 (0.76 to 1.22)
VIM+ (n=168) 7 (4.17) 47 (27.98) 114 (67.86) 18.15 0.497 0.807 0.90 (0.68 to 1.21)
IOD+ (n=96) 5 (5.21) 24 (25.00) 67 (69.79) 17.71 0.500 0.822 0.88 (0.60 to 1.28)
*All p values have been calculated for the allelic model.
†Benjamini and Hochberg step-up FDR control.
‡OR for the minor allele.
FDR, false discovery rate; GCA, giant cell arteritis; IOD, irreversible occlusive disease; MAF, minor allele frequency; PMR, polymyalgia rheumatica; SNP, single-nucleotide polymorphism;
VIM, visual ischaemic manifestations.
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association of the PTPN22 rs2476601/R620W*A allele with
GCA was observed (PFDR=1.06E-04, OR=1.62, CI 95% 1.29
to 2.04). Subsequently, to examine whether PTPN22 and CSK
polymorphisms might inﬂuence the clinical manifestations of
the disease, GCA patients were stratiﬁed according to the pres-
ence of PMR, VIM and IOD (table 1). Consistently, the subphe-
notype analysis also reached statistical signiﬁcance for the
rs2476601 polymorphism (PMR+ vs controls: PFDR=9.02E-04,
OR=1.77, CI 95% 1.30 to 2.40; VIM+ vs controls:
PFDR=4.10E-03, OR=1.82, CI 95% 1.27 to 2.62; IOD+ vs
controls: PFDR=2.19E-03, OR=2.14, CI 95% 1.38 to 3.33).
However, no statistically signiﬁcant differences between GCA
patients with and without these clinical characteristics were
observed (data not shown). No association with any other
PTPN22 and CSK genetic variants was evident either in the
case/control or subphenotype analysis (table 1).
To follow-up the positive ﬁnding of an association between
PTPN22 rs2476601/R620W and GCA in the Spanish
population, we attempted to conﬁrm the detected association in
a replication set of three independent cohorts of Caucasian
ancestry. No heterogeneity between the ORs from the three rep-
lication cohorts was evident by BD test (p=0.05), and therefore
a combined meta-analysis was performed (table 2 and online
supplementary table S2). Statistically signiﬁcant differences were
observed for the PTPN22 rs2476601*A allele in the pooled ana-
lysis (PMH=0.0154, OR=1.38, CI 95% 1.07 to 1.77) (table 2).
Subsequently, the overall meta-analysis including both the dis-
covery and the three replication cohorts showed a consistent
association between the PTPN22 rs2476601*A variant and GCA
(PMH=2.00E-06, OR=1.51, CI 95% 1.28 to 1.79; ﬁgure 1).
Again, no signiﬁcant differences were found when GCA patients
with and without speciﬁc clinical features were compared (data
not shown).
The comparisons of the different detected allelic combina-
tions between cases and controls did not yield additional infor-
mation (data not shown).
Table 2 Replication and pooled analysis of the PTPN22 rs2476601 variant in Caucasian biopsy-proven GCA patients and controls
Population Subgroup (N)
Genotype, N (%) Allele test
1/1 1/2 2/2 MAF (%) p Value* OR (CI 95%)†
Germany Controls (n=937) 9 (0.98) 164 (17.94) 741 (81.07) 9.96
GCA (n=72) 0 (0.00) 14 (19.44) 58 (80.56) 9.72 0.9280 0.97 (0.54 to 1.73)
Norway Controls (n=271) 1 (0.37) 56 (20.66) 214 (78.97) 10.70
GCA (n=60) 1 (1.67) 19 (31.67) 40 (66.67) 17.50 0.0376 1.77 (1.03 to 3.05)
UK Controls (n=5199) 42 (0.80) 933 (17.95) 4224 (81.25) 9.78
GCA (n=156) 3 (1.92) 36 (23.08) 117 (75.00) 13.46 0.0319 1.44 (1.03 to 2.00)
Replication meta-analysis‡ Controls (n=6384) 52 (0.81) 1153 (18.06) 5179 (81.12) 9.84
GCA (n=288) 4 (1.39) 69 (23.96) 215 (74.65) 13.37 0.0154 1.38 (1.07 to 1.77)
Overall meta-analysis§ Controls (n=8113) 65 (0.80) 1353 (16.68) 6695 (82.52) 9.14
GCA (n=911) 8 (0.88) 188 (20.64) 715 (78.49) 11.20 2.00E-06 1.51 (1.28 to 1.79)
*All p values have been calculated for the allelic model.
†OR for the minor allele.
‡Including independent cohorts from Germany, Norway and UK.
§Including independent cohorts from Spain, Germany, Norway and UK.
GCA, giant cell arteritis.
Figure 1 Forest plot showing the ORs and CIs of the PTPN22 rs2476601 association in the discovery and replication cohorts. OR and CI were
calculated under the ﬁxed effect model.
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DISCUSSION
Our data indicate, for the ﬁrst time, an important role for PTPN22
in the genetic susceptibility of GCA. The combined analysis of the
four independent cohorts showed a strong association between the
PTPN22 rs2476601/R620W variant and this disease. The effect
size detected in our study (OR=1.51) is similar to that described
for other autoimmune conditions, such as rheumatoid arthritis
(OR=1.45), SLE (OR=1.45) or type 1 diabetes mellitus
(OR>1.80)6 7 and, interestingly, for other vasculitides, such as
Behçet’s disease (OR>2.0) or antineutrophil cytoplasmic
antibodies-associated vasculitis (OR>1.90).18 19 Despite this, a
previous study failed to show association between PTPN22
rs2476601 and GCA20; however, it should be noted that the statis-
tical power of this study was compromised because of the small
sample size included in this report (96 GCA cases and 229 con-
trols). In the subphenotype analysis, no speciﬁc association with
any analysed clinical feature was observed, indicating that this
variant may represent a risk factor for the global disease.
Nevertheless, this should be taken with caution because of the low
statistical power, which was a limitation of this stratiﬁed analysis.
Regarding CSK, our analysis had enough statistical power to
detect a possible weak signal (power > 80% to detect an
OR>1.25 in the discovery cohort); therefore, it is unlikely that
CSK may play an important role in GCA susceptibility. Since an
association between PTPN22 and GCA was observed, it makes
sense that its interacting partner, CSK, may also play a role in this
pathology, but in most of the diseases in which an involvement of
PTPN22 has been described, an association with CSK has not
been reported. Nevertheless, an effect of other CSK polymorph-
isms, showing low linkage disequilibrium with those analysed in
our study, in GCA susceptibility cannot be discarded.
Initially, the PTPN22 allele rs2476601*A, located within a
protein–protein interaction domain, was reported as a
gain-of-function allele that causes a decrease in TCR signal-
ling.12 However, a recent study has reported that this variant is
a loss-of-function allele, leading to an accelerated degradation of
lyp that results in enhanced signalling in several immune cell
types.13 Although the mechanisms underlying the role of the
PTPN22 rs2476601 genetic variant in autoimmunity remain
unclear, the association of this SNP with GCA suggests that a
deregulation of TCR signalling is involved in the pathophysio-
logical mechanisms of this vasculitis.
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